Abstract
Purpose
Cisplatin, one of the most effective anticancer drugs, is known to cause undesirable adverse effects, including immunotoxicity. Echinacea purpurea is an important medicinal plant with immunostimulatory and anti-inflammatory activities. We have investigated the protective effect of an herbal formulation (Immulant) containing E. purpurea extract against cisplatin-induced immunotoxicity in rats.
Methods
Forty mature albino rats were randomized into four groups (10 rats/group). Control (group 1) animals were subjected to intraperitoneal (i.p.) injection of saline solution (0.2 ml) once every 3 days. Group 2 animals received cisplatin (3.5 mg/kg, i.p.) once every 3 days for successive 2 weeks. Group 3 rats received oral Immulant (150 mg/kg) once daily for 2 weeks. Group 4 animals received oral Immulant treatment as in group 3 in addition to cisplatin as in group 2. Serum level of total protein and albumin, total and differential leukocytic count, phagocytic activity of monocytes, humoral activity and splenic histopathology and immunohistochemistry were used as diagnostic markers of immunotoxicity.
Results
Cisplatin induced marked inhibition of cellular immunity as exhibited by significant decrease of leukocytic count, lymphocyte percentage and phagocytic activity with marked increase in neutrophil percentage. Humoral immunity represented by marked inhibition in total protein and γ-globulin concentration and significant inhibition in antibody titer against Mycoplasma gallisepticum were recorded. Histopathological and immunohistochemical observation of the spleen of cisplatin-treated rats revealed obvious pathological findings of marked depletion and degeneration of lymphoid tissue. Co-oral administration of Immulant resulted in substantial improvement of various immunotoxicological indices compared to cisplatin control.
Conclusion
The herbal medicine Immulant is an immunostimulant which could be used to treat the immunotoxic effects of cisplatin.
Similar content being viewed by others
References
Baek SM, Kwon CH, Kim JH, Woo JS, Jung JS, Kim YK. Differential roles of hydrogen peroxide and hydroxyl radical in cisplatin-induced cell death in renal proximal tubular epithelial cells. J Lab Clin Med. 2003;142:178–86.
Hasaaan I, Chibber S, Naseem I. Ameliorative effect of riboflavin on the cisplatin induced nephrotoxicity and hepatotoxicity under photoillumination. Food Chem Toxicol. 2010;48:2050–8.
Jordan P, Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci. 2000;57:1229–35.
Zandvoort A, Lodewijk ME, Klok PA, Dammers PM, Kroese FG, Timens W. Slow recovery of follicular B cells and marginal zone B cells after chemotherapy: implications for humoral immunity. Clin Exp Immunol. 2001;124:172–9.
Onsrud M, Bosnes V, Grahm I. Cis-platinum as adjunctive to surgery in early stage ovarian carcinoma: effects on lymphoid cell subpopulations. Gynecol Oncol. 1986;23:323–8.
Lee TT, Chen CL, Shieh ZH, Lin JC, Yu B. Study on antioxidant activity of Echinacea purpurea L. extracts and its impact on cell viability. Afr J Biotechnol. 2009;8:5097–105.
Matthias A, Banbury L, Bone KM, Leach DN, Lehmann RP. Echinacea alkylamides modulate induced immune responses in T-cells. Fitoterapia. 2008;79:53–8.
Wang Y, Chen L, Huang G, He D, He J, Xu W, et al. Klotho sensitizes human lung Cancer cell line to cisplatin via PI3k/Akt pathway. PLoS One. 2013;8:573–91.
Zhai Z, Liu Y, Wu L, Senchina DS, Wurtele ES, Murphy PA, et al. Enhancement of innate and adaptive immune functions by multiple Echinacea species. J Med Food. 2007;10:423–34.
Paget GE, Barnes JM. Toxicity tests. In: Laurence DR, Bachorach AL, editors. Evaluation of drug activities: Pharmacomertrics. New York: Academic Press; 1964. p. 133–66.
Zink T, Chaffin J. Herbal ‘Health’ products: what family physicians need to know. Am Fam Physician. 1998;58:1133–40.
Schalm OW, Jain NE, Caroll EJ. Veterinary haematology. 3rd ed. Philadelphia: Lea and Febiger; 1975.
Gornall AG, Bardawill CJ, David MM. Determination of serum proteins by means of the biuret reaction. J Biol Chem. 1949;177:751–66.
Doumas BT, Watson WA, Biggs HG. Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta. 1971;31:87–96.
Kaplan A, Saveloy J. Evaluation of a cellulose-acetate electrophoresis system for serum fractionation. Clin Chem. 1965;11:937.
Anthony TWC, Twin KML, Erin MW, Michael EM. Phagocytic and killing capacities of uterine derived leukocytes from mares resistant and susceptible to chronic endometritis. Am J Vet Res. 1985;46:1938–40.
Chu Y, Dietert RR. Monocyte function in chicken with hereditary dystrophy. J Poult Sci. 1989;68:226–32.
Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest Suppl. 1968;21:77–89.
Hanks DH, Waalace OH. Determination of cell viability. Proc Soc Exp Biol Med. 1985;98:183–92.
Bancroft JD, Gamble M. Theory and practice of histological techniques. 6th ed. Edinburgh, London and New York: Churchill Livingston; 2007.
Ramos-Vara JA. Technical aspects of immunohistochemistry. Vet Pathol. 2005;42:405–26.
Wijermans PW, Gerrits WB, Haak HL. Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol. 1993;50:292–6.
Park KP, Lee BC, Lee JS, Cho MH. Angelica gigas Nakai extract ameliorates the effects of cyclophosphamide on immunological and hematopoietic dysfunction in mice. J Med Plant Res. 2014;8:657–63.
Awadallah AM, Moussa FI, Abad El Hameed N. Treatment of cisplatin Haematotoxicity with Lasix or selenium or both in adult male rabbits. Pak J Biol Sci. 2001;4:89–93.
Pieretti M, Hopenhayn-Rich C, Khattar NH, Cao Y, Huang B, Tucker TC. Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival. Cancer Investig. 2002;20:11–23.
Gale RP. Antineoplastic chemotherapy myelosuppression: mechanisms and new approaches. Exp Hematol. 1985;13:3–7.
Markovic SD, Zˇizic JB, Djacic DS, Obradovic AD, MG C’u, Cvetkovic DM, et al. Alteration of oxidative stress parameters in red blood cells of rats after chronic in vivo treatment with cisplatin and selenium. Arch Biol Sci. 2011;63:991–9.
Bhoopendra K, Nitesh K. Immunotoxicity of lambda-Cyhalothrin in Wistar albino rats. International Journal of Toxicological and Pharmacological Research. 2014;6:47–56.
Jílek P, Dvoráková J, Turecková J, Procházková J. The effect of platinum cytostatics on delayed-type hypersensitivity in mice. Neoplasma. 1989;36:659–65.
Li XB, Schluesener HJ. Therapeutic effects of cisplatin on rat experimental autoimmune encephalomyelitis. Arch Immunol Ther Exp. 2006;54:51–3.
Kouchi Y, Maeda Y, Ohuchida A, Ohsawa M. Immunotoxic effect of low dose cisplatin in mice. J Toxicol Sci. 1996;21:227–33.
Hegab S, MutawaS A. Immunopathogenesis of Bebeet′s disease. Clin Immunol. 2000;96:174–86.
Kuper CF, Schuurman HJ, Vos JG. Pathology in immunotoxicology. In: Burleson GR, Dean JH, Munson AE, editors. Methods in immunotoxicology. New York: Wiley-Liss; 1995. p. 397–436.
Kuper CF, Harleman JH, Richter-Reichhelm HB, Vos JG. Histopathologic approaches to detect changes indicative of immunotoxicity. Toxicol Pathol. 2000;28:454–66.
Kuper CF, deHeer E, Van Loveren H, Vox JG. Immune system. In: Haschek W, Rousseaux CG, Wallig MA, editors. Handbook of toxicological pathology. San Diego: Academic Press; 2002. p. 585–646.
Descotes J. Methods of evaluating immunotoxicity. Expert Opin Drug Metab Toxicol. 2006;2:249–59.
Pearse G, Pietersma A, Cunliffe J, Foster JR, Turton J, Derbyshire N, et al. Time-course study of the immunotoxic effects of the anticancer drug chlorambucil in the rat. Toxicol Pathol. 2009;37:887–901.
Monfared AL, Jaafari A, Sheibani M. Histological and histometrical evidences for phenol immunotoxicity in mice. Comp Clin Pathol. 2014;23:529–53.
Menezes SL, Bozza PT, Neto HC, Laranjeira AP, Negri EM, Capelozzi VL, et al. Pulmonary and extrapulmonary acute lung injury: inflammatory and ultrastructural analyses. J Appl Physiol. 2005;98:1777–83.
Crăciun C, Paşca C. Structural and ultrastructural data on side effects of cisplatin in spleen, kidney and liver of rats. Acta Metallomica – MEEMB. 2014;11:9–22.
Tuorkey MJ. Cancer therapy with phytochemicals: present and future perspectives. Biomed Environ Sci. 2015;28:808–19.
Liang B, Wang S, Ye YJ, Yang XD, Wang YL, Qu J, et al. Impact of postoperative omega-3 fatty acid-supplemented parenteral nutrition on clinical outcomes and immunomodulations in colorectal cancer patients. World J Gastroenterol. 2008;14:2434–9.
Mantovani MS, Bellini MF, Angeli JP, Oliveira RJ, Silva AF, Ribeiro LR. Beta-glucans in promoting health: prevention against mutation and cancer. Mutat Res. 2008;658:154–61.
Badhani B, Sharma N, Kakkar R. Gallic acid: a versatile antioxidant with promising therapeutic and industrial applications. RSC Advances. 2015;5:27540–57.
Barrett B. Medicinal properties of Echinacea: a critical review. Phytomedicine. 2003;10:66–86.
Cundell DR, Matrone MA, Ratajczak P, Pierce JD Jr. The effect of aerial parts of Echinacea on the circulating white cell levels and selected immune functions of the aging male Sprague-Dawley rat. Int Immunopharmacol. 2003;3:1041–8.
Kim LS, Waters RF, Burkholder PM. Immunological activity of larch arabinogalactan and Echinacea: a preliminary, randomized, double-blind, placebo-controlled trial. Altern Med Rev. 2002;7:138–49.
Echinacea BR. Biological effects and active principals, phytomedicines of Europe: chemistry and biological activity. In: Lawson LD, Bauer R, editors. ACS symposium series, vol. 691. Washington, DC: American Chemical Society; 1998. p. 140–57.
Chen Y, Fu T, Tao T, Yang I, Chang Y, Kim L. Macrophage activating effect of new alkamides from the roots of Echinacea species. J Nat Prod. 2005;68:773–6.
Merali S, Bnns S, Paulin-Levasseur M, Ficker C, Smith M, Baum BR. Antifungal and anti-inflammatory activity of the genus Echinacea. Pharm Biol. 2003;41:412–20.
Wills RB, Bone K, Morgan M. Herbal products: active constituents, modes of action and quality control. Nutr Res Rev. 2000;13:47–77.
Thygesen L, Thulin J, Mortensen A, Skibsted LH, Molgaard P. Antioxidant activity of cichoric acid and alkamides from Echinacea purpurea, alone and in combination. Food Chem. 2007;101:74–81.
Acknowledgements
The authors express their sincere thanks to Prof. Sheren Ghalebfor review of the manuscript.
Author information
Authors and Affiliations
Contributions
All authors participated in the design, interpretation of the study, analysis of the data, and review of the manuscript.
Corresponding authors
Ethics declarations
Ethics approval
All animal studies were performed in accordance with the procedure approved by the Institutional Animal Care and Use Committee of Cairo University (IACUC, CU-II-F-10-19).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Khalaf, A.A., Hussein, S., Tohamy, A.F. et al. Protective effect of Echinacea purpurea (Immulant) against cisplatin-induced immunotoxicity in rats. DARU J Pharm Sci 27, 233–241 (2019). https://doi.org/10.1007/s40199-019-00265-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40199-019-00265-4